Papapetropoulos Spyros 4
4 · Neuphoria Therapeutics Inc. · Filed Sep 2, 2025
Insider Transaction Report
Form 4
Papapetropoulos Spyros
DirectorPresident and CEO
Transactions
- Award
Employee Stock Option (Right-to- Buy)
2025-08-27$8.27/sh+34,559$285,803→ 74,088 totalExercise: $8.27Exp: 2035-08-27→ Common Stock (34,559 underlying)
Footnotes (1)
- [F1]Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested.